Becton, Dickinson and Co. (BDX – Q4FY20 & FY20) – Quarter performance positively affected by COVID-19 testing revenue.

BD Life Sciences segment, revenues for the quarter of $1.488bn increased 31.2% over the prior-year period. The segment’s results were driven by strong sales related to COVID-19 diagnostic testing solutions in the Diagnostic Systems unit on the BD VeritorTM and BD MaxTM platforms.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q4FY20 Results – Overview.
– FY20 Results – Overview
– Q4FY20 & FY20– Geographic Revenues
– Q4FY20 & FY20 – Segment Performance
– Q4FY20 – Key Developments
– FY20 Guidance
– Conclusion
– GAAP to Non-GAAP Reconciliation

 Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– DuPont Analysis
– ROIC
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

Crispidea Coverage

No of Pages : 64